Impaired peroxisome proliferator-activated receptor γ function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy

Molecular Endocrinology

Volumn 21, Issue 5, 2007, Pages 1049-1065

  Jeninga, Ellen H ^a   Van Beekum, Olivier ^a   Van Dijk, Aalt D J ^b   Hamers, Nicole ^a   Hendriks Stegeman, Brenda I ^a   Bonvin, Alexandre M J J ^b   Berger, Ruud ^a   Kalkhoven, Eric ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA;

ADIPOCYTE; ADIPOGENESIS; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL TYPE; CONTROLLED STUDY; DIMERIZATION; EMBRYO; FAMILIAL PARTIAL LIPODYSTROPHY TYPE 3; GENE MUTATION; GENETIC CONSERVATION; GENETIC TRANSCRIPTION; HAPLOTYPE; HUMAN; HUMAN CELL; LIGAND BINDING; LIPODYSTROPHY; MOLECULAR DYNAMICS; MOLECULAR GENETICS; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN STRUCTURE; SIMULATION; STRUCTURE ANALYSIS; WILD TYPE;

AMINO ACID SUBSTITUTION; ARGININE; BASE SEQUENCE; BONE NEOPLASMS; CELL LINE, TUMOR; CYSTEINE; DNA; DNA MUTATIONAL ANALYSIS; DNA PROBES; HETEROZYGOTE DETECTION; HUMANS; LIPODYSTROPHY, FAMILIAL PARTIAL; MODELS, MOLECULAR; OSTEOSARCOMA; PPAR GAMMA; PROTEIN CONFORMATION; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 34250831418     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2006-0485     Document Type: Article

References (80)

1. Friedman JM 2003 A war on obesity, not the obese. Science 299:856-858
2. Simha V, Garg A 2006 Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol 17:162-169
3. Capeau J, Magre J, Lascols O, Caron M, Bereziat V, Vigouroux C, Bastard JP 2005 Diseases of adipose tissue: genetic and acquired lipodystrophies. Biochem Soc Trans 33:1073-1077
4. Garg A 2004 Acquired and inherited lipodystrophies. N Engl J Med 350:1220-1234
5. Nolan D, Mallal S 2004 Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 9:849-863
6. Semple RK, Chatterjee VK, O'Rahilly S 2006 PPARγ and human metabolic disease. J Clin Invest 116:581-589
7. Hegele RA 2005 Lessons from human mutations in PPARgamma. Int J Obes (Lond) 29(Suppl 1):S31-S35
8. Willson TM, Brown PJ, Sternbach DD, Henke BR 2000 The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550
9. Lehrke M, Lazar MA 2005 The many faces of PPARγ. Cell 123:993-999
10. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W 2006 From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45:120-159
11. Tontonoz P, Hu E, Spiegelman BM 1994 Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79:1147-1156
12. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM 1999 PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585-595
13. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T 1999 PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609
14. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM 1999 PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611-617
15. Evans RM, Barish GD, Wang YX 2004 PPARs and the complex journey to obesity. Nat Med 10:355-361
16. Gampe Jr RT, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, Xu HE 2000 Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell 5:545-555
17. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV 1998 Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395:137-143
18. Yu C, Markan K, Temple KA, Deplewski D, Brady MJ, Cohen RN 2005 The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor γ transcriptional activity and repress 3T3-L1 adipogenesis. J Biol Chem 280:13600-13605
19. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA 2005 Corepressors selectively control the transcriptional activity of PPARγ in adipocytes. Genes Dev 19:453-461
20. Chui PC, Guan HP, Lehrke M, Lazar MA 2005 PPARγ regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1. J Clin Invest 115:2244-2256
21. Westin S, Kurokawa R, Nolte RT, Wisely GB, McInerney EM, Rose DW, Milburn MV, Rosenfeld MG, Glass CK 1998 Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature 395:199-202
22. Perissi V, Rosenfeld MG 2005 Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 6:542-554
23. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 1995 15-Deoxy-δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812
24. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W 1997 Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11:779-791
25. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956
26. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington Jr WW, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook Jr RA, Noble SA, Oliver Jr W, Parks DJ, Plunket KD, Szewczyk JR, Willson TM 1998 N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 41:5020-5036
27. Sethi JK, Hotamisligil GS 1999 The role of TNFα in adipocyte metabolism. Semin Cell Dev Biol 10:19-29
28. Ruan H, Lodish HF 2003 Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α. Cytokine Growth Factor Rev 14:447-455
29. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S 1999 Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883
30. Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T 2002 PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51:3586-3590
31. Agarwal AK, Garg A 2002 A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87:408-411
32. Agostini M, Schoenmakers E, Mitchell C, Szatmari I, Savage D, Smith A, Rajanayagam O, Semple R, Luan J, Bath L, Zalin A, Labib M, Kumar S, Simpson H, Blom D, Marais D, Schwabe J, Barroso I, Trembath R, Wareham N, Nagy L, Gurnell M, O'Rahilly S, Chatterjee K 2006 Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance. Cell Metab 4:303-311
33. Francis GA, Li G, Casey R, Wang J, Cao H, Leff T, Hegele RA 2006 Peroxisomal proliferator activated receptor-γ deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med Genet 7:3
34. Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schafer AJ 2002 Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 31:379-384
35. Brelivet Y, Kammerer S, Rochel N, Poch O, Moras D 2004 Signature of the oligomeric behaviour of nuclear receptors at the sequence and structural level. EMBO Rep 5:423-429
36. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S 1992 The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11:433-439
37. Agostini M, Gurnell M, Savage DB, Wood EM, Smith AG, Rajanayagam O, Garnes KT, Levinson SH, Xu HE, Schwabe JW, Willson TM, O'Rahilly S, Chatterjee VK 2004 Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor γ. Endocrinology 145:1527-1538
38. Kondo H, Shimomura I, Kishida K, Kuriyama H, Makino Y, Nishizawa H, Matsuda M, Maeda N, Nagaretani H, Kihara S, Kurachi Y, Nakamura T, Funahashi T, Matsuzawa Y 2002 Human aquaporin adipose (AQPap) gene. Genomic structure, promoter analysis and functional mutation. Eur J Biochem 269:1814-1826
39. Molnar F, Matilainen M, Carlberg C 2005 Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. J Biol Chem 280:26543-26556
40. Yen PM 2003 Molecular basis of resistance to thyroid hormone. Trends Endocrinol Metab 14:327-333
41. Clifton-Bligh RJ, de Zegher F, Wagner RL, Collingwood TN, Francois I, Van Helvoirt M, Fletterick RJ, Chatterjee VK 1998 A novel TR beta mutation (R383H) in resistance to thyroid hormone syndrome predominantly impairs corepressor release and negative transcriptional regulation. Mol Endocrinol 12:609-621
42. Fawell SE, Lees JA, White R, Parker MG 1990 Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 60:953-962
43. Chen S, Johnson BA, Li Y, Aster S, McKeever B, Mosley R, Moller DE, Zhou G 2000 Both coactivator LXXLL motif-dependent and -independent interactions are required for peroxisome proliferator-activated receptor γ (PPARγ) function. J Biol Chem 275:3733-3736
44. Schulman IG, Shao G, Heyman RA 1998 Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor γ (PPARγ) heterodimers: intermolecular synergy requires only the PPARγ hormone-dependent activation function. Mol Cell Biol 18:3483-3494
45. Gelman L, Zhou G, Fajas L, Raspe E, Fruchart JC, Auwerx J 1999 p300 interacts with the N- and C-terminal part of PPARγ2 in a ligand-independent and -dependent manner, respectively. J Biol Chem 274:7681-7688
46. Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P, Cato AC 1997 lκBα-independent downregulation of NF-κB activity by glucocorticoid receptor. EMBO J 16:4698-4707
47. Suzawa M, Takada I, Yanagisawa J, Ohtake F, Ogawa S, Yamauchi T, Kadowaki T, Takeuchi Y, Shibuya H, Gotoh Y, Matsumoto K, Kato S 2003 Cytokines suppress adipogenesis and PPAR-γ function through the TAK1/TAB1/NIK cascade. Nat Cell Biol 5:224-230
48. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, Chatterjee VK 2000 A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. J Biol Chem 275:5754-5759
49. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK 2005 A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437:759-763
50. Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, McKee DD, Galardi CM, Plunket KD, Nolte RT, Parks DJ, Moore JT, Kliewer SA, Willson TM, Stimmel JB 2002 Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα. Nature 415:813-817
51. Vaisanen S, Duchier C, Rouvinen J, Maenpaa PH 1999 The importance of the putative helices 4 and 5 of human vitamin D(3) receptor for conformation and ligand binding. Biochem Biophys Res Commun 264:478-482
52. Vivat-Hannah V, Bourguet W, Gottardis M, Gronemeyer H 2003 Separation of retinoid X receptor homo- and heterodimerization functions. Mol Cell Biol 23:7678-7688
53. Collingwood TN, Adams M, Tone Y, Chatterjee VK 1994 Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone β-receptors in thyroid hormone resistance syndrome. Mol Endocrinol 8:1262-1277
54. Nagaya T, Jameson JL 1993 Thyroid hormone receptor dimerization is required for dominant negative inhibition by mutations that cause thyroid hormone resistance. J Biol Chem 268:15766-15771
55. Al Shali K, Cao H, Knoers N, Hermus AR, Tack CJ, Hegele RA 2004 A single-base mutation in the peroxisome proliferator-activated receptor γ4 promoter associated with altered in vitro expression and partial lipodystrophy. J Clin Endocrinol Metab 89:5655-5660
56. Tsai YS, Maeda N 2005 PPARγ: a critical determinant of body fat distribution in humans and mice. Trends Cardiovasc Med 15:81-85
57. Gray SL, Dalla NE, Vidal-Puig AJ 2005 Mouse models of PPAR-γ deficiency: dissecting PPAR-γ's role in metabolic homoeostasis. Biochem Soc Trans 33:1053-1058
58. Ausubel FM, Brent R, Kingston R, Moore D, Seidman JJ, Smith J, Struhl K 1993 Current protocols in molecular biology. New York: John Wiley & Sons
59. Burstein E, Hoberg JE, Wilkinson AS, Rumble JM, Csomos RA, Komarck CM, Maine GN, Wilkinson JC, Mayo MW, Duckett CS 2005 COMMD proteins, a novel family of structural and functional homologs of MURR1. J Biol Chem 280:22222-22232
60. Ge K, Guermah M, Yuan CX, Ito M, Wallberg AE, Spiegelman BM, Roeder RG 2002 Transcription coactivator TRAP220 is required for PPARγ2-stimulated adipogenesis. Nature 417:563-567
61. Chen JD, Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-457
62. Kalkhoven E, Valentine JE, Heery DM, Parker MG 1998 Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J 17:232-243
63. Wissink S, van Heerde EC, Schmitz ML, Kalkhoven E, van der BB, Baeuerle PA, van der Saag PT 1997 Distinct domains of the RelA NF-κB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor. J Biol Chem 272:22278-22284
64. Kalkhoven E, Teunissen H, Houweling A, Verrijzer CP, Zantema A 2002 The PHD type zinc finger is an integral part of the CBP acetyltransferase domain. Mol Cell Biol 22:1961-1970
65. Ribeiro RC, Feng W, Wagner RL, Costa CH, Pereira AC, Apriletti JW, Fletterick RJ, Baxter JD 2001 Definition of the surface in the thyroid hormone receptor ligand binding domain for association as homodimers and heterodimers with retinoid X receptor. J Biol Chem 276:14987-14995
66. Butler AJ, Parker MG 1995 COUP-TF II homodimers are formed in preference to heterodimers with RXRα or TRβ in intact cells. Nucleic Acids Res 23:4143-4150
67. van der BB, Rutteman GR, Blankenstein MA, de Laat SW, van Zoelen EJ 1988 Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and estrogen. J Cell Physiol 134:101-108
68. Adams M, Matthews C, Collingwood TN, Tone Y, Beck-Peccoz P, Chatterjee KK 1994 Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. Identification of thirteen novel mutations in the thyroid hormone receptor β gene. J Clin Invest 94:506-515
69. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F 2002 Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034
70. Lindahl E, Hess B, van der Spoel D 2001 GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Model 7:306-317
71. Berendsen HJC, Vanderspoel D, Vandrunen R 1995 Gromacs - a message-passing parallel molecular-dynamics implementation. Comp Phys Commun 91:43-56
72. Daura X, Jaun B, Seebach D, van Gunsteren WF, Mark AE 1998 Reversible peptide folding in solution by molecular dynamics simulation. J Mol Biol 280:925-932
73. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE 2000 The Protein Data Bank. Nucleic Acids Res 28:235-242
74. Berendsen HJC, Postma JPM, van Gunsteren WF 1981 Interaction models for water in relation to protein hydration. In: Pullman B, ed. Intermolecular forces. Dordrecht, The Netherlands: Reidel; 331-342
75. Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR 1984 Molecular dynamics with coupling to an external bath. J Chem Phys 81:3684-3690
76. Hess B, Bekker H, Berendsen HJC, Fraaije JGEM 1997 LINCS: a linear constraint solver for molecular simulations. J Comput Chem 18:1463-1472
77. Vangunsteren WF, Berendsen HJC 1990 Computer-simulation of molecular-dynamics - methodology, applications, and perspectives in chemistry. Angewandte Chemie (International Edition in English) 29:992-1023
78. Tironi IG, Sperb R, Smith PE, Vangunsteren WF 1995 A generalized reaction field method for molecular-dynamics simulations. J Chem Phys 102:5451-5459
79. Kraulis PJ 1991 MolScript - a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24:946-950
80. Merritt EA, Murphy MEP 1994 Raster3D Version 2.0 - a program for photorealistic molecular graphics. Acta Crystallogr D 50:869-873